Literature DB >> 3154307

Preclinical studies on angiotensin converting enzyme inhibitors.

I L Natoff1.   

Abstract

The identification of the renin-angiotensin-aldosterone system in the control of blood pressure, and the preclinical development of the angiotensin converting enzyme inhibitors for therapeutic use are reviewed. The properties of these compounds are discussed with respect to their in vitro enzyme inhibitory potency; prevention of the pharmacological effects of angiotensin I; potentiation of those of bradykinin; tissue enzyme inhibition; mechanism of effect on blood pressure both alone and in combination with other antihypertensive agents; and effect on cardiac parameters.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3154307     DOI： 10.1007/bf02125829

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


  114 in total

1.  Renin in Experimental Hypertension.

Authors:  B A Houssay; E Braun-Menendez
Journal:  Br Med J       Date:  1942-08-15

2.  Subcellular localization of pulmonary antiotensin-converting enzyme (kininase II).

Authors:  J W Ryan; U S Ryan; D R Schultz; C Whitaker; A Chung
Journal:  Biochem J       Date:  1975-02       Impact factor: 3.857

3.  Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats.

Authors:  T Unger; D Ganten; R E Lang; B A Schölkens
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jan-Feb       Impact factor: 3.105

4.  Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis.

Authors:  M A Ondetti; N J Williams; E F Sabo; J Pluscec; E R Weaver; O Kocy
Journal:  Biochemistry       Date:  1971-10-26       Impact factor: 3.162

5.  Selective activation of the converting enzyme inhibitor MK 421 and comparison of its active diacid form with captopril in different tissues of the rat.

Authors:  T Unger; B Schüll; W Rascher; R E Lang; D Ganten
Journal:  Biochem Pharmacol       Date:  1982-10-01       Impact factor: 5.858

6.  Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats.

Authors:  M J Antonaccio; B Rubin; Z P Horovitz; R J Laffan; M E Goldberg; J P High; D N Harris; I Zaidi
Journal:  Jpn J Pharmacol       Date:  1979-04

7.  Unchanged pressor effect of norepinephrine in normal man following the oral administration of two angiotensin converting enzyme inhibitors, captopril and HOE 498.

Authors:  H Vierhapper; P U Witte; W Waldhäusl
Journal:  J Hypertens       Date:  1986-02       Impact factor: 4.844

8.  Effects of an orally active converting-enzyme inhibitor, SQ 14225, on pressor responses to angiotensin administered into the brain ventricles of spontaneously hypertensive rats.

Authors:  J F Mann; W Rascher; R Dietz; A Schömig; D Ganten
Journal:  Clin Sci (Lond)       Date:  1979-01       Impact factor: 6.124

9.  The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog.

Authors:  A J Riegger; G Liebau
Journal:  Clin Sci (Lond)       Date:  1982-05       Impact factor: 6.124

10.  The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects.

Authors:  J F Giudicelli; A Berdeaux; A Edouard; C Richer; D Jacolot
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335
View more
  1 in total

1.  Proceedings of the British Pharmacological Society. Liverpool, 6th-8th April, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.